Delcath Systems Inc
NASDAQ:DCTH

Watchlist Manager
Delcath Systems Inc Logo
Delcath Systems Inc
NASDAQ:DCTH
Watchlist
Price: 11.1714 USD -2.35%
Market Cap: 357.1m USD
Have any thoughts about
Delcath Systems Inc?
Write Note

Delcath Systems Inc
Retained Earnings

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Delcath Systems Inc
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
Delcath Systems Inc
NASDAQ:DCTH
Retained Earnings
-$528.2m
CAGR 3-Years
-8%
CAGR 5-Years
-7%
CAGR 10-Years
-8%
Becton Dickinson and Co
NYSE:BDX
Retained Earnings
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Retained Earnings
$2.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Stryker Corp
NYSE:SYK
Retained Earnings
$18.3B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
9%
Abbott Laboratories
NYSE:ABT
Retained Earnings
$39.1B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
6%
Intuitive Surgical Inc
NASDAQ:ISRG
Retained Earnings
$6.1B
CAGR 3-Years
12%
CAGR 5-Years
23%
CAGR 10-Years
33%
No Stocks Found

Delcath Systems Inc
Glance View

Market Cap
357.1m USD
Industry
Health Care

Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. The company is headquartered in New York City, New York and currently employs 45 full-time employees. The company went IPO on 2000-10-19. The firm's lead product candidate, the HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) is a drug/device combination product. HEPZATO KIT is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, its commercial product is a medical device having the same device components as the HEZPATO KIT but without the melphalan hydrochloride, is designated as a Class III medical device, and is sold under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT), where it is being used at various medical centers to treat a range of cancers of the liver. In the United States, HEPZATO KIT is considered a combination drug and device product. The firm's product administers concentrated regional chemotherapy to the liver.

DCTH Intrinsic Value
12.951 USD
Undervaluation 14%
Intrinsic Value
Price

See Also

What is Delcath Systems Inc's Retained Earnings?
Retained Earnings
-528.2m USD

Based on the financial report for Sep 30, 2024, Delcath Systems Inc's Retained Earnings amounts to -528.2m USD.

What is Delcath Systems Inc's Retained Earnings growth rate?
Retained Earnings CAGR 10Y
-8%

Over the last year, the Retained Earnings growth was -7%. The average annual Retained Earnings growth rates for Delcath Systems Inc have been -8% over the past three years , -7% over the past five years , and -8% over the past ten years .

Back to Top